Highest-materiality recent filing
BNB Plus stockholders approve reverse stock split authorization (1:5 to 1:30)
Vote: 2,420,538 for, 317,840 against, 11,866 abstained on reverse split proposal.
BNB Plus receives Nasdaq delisting notice for bid price non-compliance; ineligible for grace period
Nasdaq notified BNB Plus on March 20, 2026 that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Mar 19.
BNB Plus appoints digital asset veteran James Haft as independent director
James Haft appointed to board and Nominating Committee effective Feb 2, 2026.
Director Elizabeth M. Schmalz Shaheen resigns from BNB Plus board effective Jan. 15, 2026
Elizabeth M. Schmalz Shaheen resigned as director of BNB Plus on January 15, 2026.
BNB Plus stockholders approve increase in authorized shares to 500M and amend equity plan
Proposal to authorize exercisability of pre-funded warrants and issuance of underlying common stock passed with 1,642,390 votes for.
Applied DNA rebrands to BNB Plus Corp., appoints Josh Kruger as Board Chairman
Name changed to BNB Plus Corp. effective Nov 13, 2025; ticker remains BNBX on Nasdaq.
Applied DNA Sciences appoints Joshua Kruger as Chairman, replacing Judith Murrah
Appointment effective November 6, 2025; Kruger also becomes director, filling vacancy from Sanford Simon's resignation.
Applied DNA Sciences enters $8.16M ATM offering and consulting deal with Patrick Horsman
ATM agreement with Lucid Capital Markets for up to $8,157,932 of common stock at market prices.
Applied DNA closes $27M PIPE, buys 15,555 BNB tokens, launches digital asset treasury
Gross proceeds of ~$27M from PIPE, with potential additional $31M from warrant exercises.
Applied DNA cuts 60% of workforce ($1.4M charges), ticker changes to BNBX Oct 7
Reduces workforce by 16 employees (~60%) with estimated pre-tax charges of ~$1.4M for severance and benefits.
APDN raises $27M via PIPE for BNB treasury strategy; CEO replaced, ticker to change to BNBX
Gross proceeds ~$27M from private placement of shares & warrants; up to $58M if warrants exercised; proceeds to acquire BNB tokens.
Applied DNA Sciences raises $26.8M, appoints new CEO, adopts BNB treasury strategy
Raised approximately $26.8 million via private placement selling 4.73M shares and warrants at $3.82 per share.
Applied DNA Q3 FY2025 revenue $304K, operating loss $3.7M; cash burn improves 19% sequentially
Total revenues $304K (down 36% YoY from $473K); operating loss $3.7M vs $3.3M loss in prior year.
Applied DNA regains Nasdaq minimum bid price compliance; hearing cancelled
On July 2, 2025, Nasdaq notified Applied DNA it regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).
Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab
Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.
Applied DNA CEO James Hayward retires; President Judy Murrah named CEO and Chair
CEO and Chairman James Hayward retires effective June 18, 2025, after 20-year tenure.
Applied DNA Sciences receives Nasdaq delisting notice for bid price deficiency; requests hearing
Nasdaq notified APDN on May 30, 2025 that bid price closed below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).
Applied DNA announces 1-for-15 reverse stock split effective June 2, 2025
Reverse stock split ratio set at 1-for-15; effective 12:01 a.m. ET on June 2, 2025.
Applied DNA shareholders approve reverse split, warrant exercise, share increase at annual meeting
All six director nominees elected (Hayward, Catell, Ceccoli, Shamash, Simon, Shaheen) with average ~572K for vs ~117K withheld.
On June 17, 2025, the Board elected Judith Murrah, the Company’s current President, as Chief Executive Officer and as Chairperson and a member of the Board effective June 18, 2025.
On June 16, 2025, Dr. James A. Hayward informed Applied DNA Sciences, Inc. (the “Company”) of his intention to retire from the Company and that he will step down from his positions as Chief Executive Officer, member of the Company’s board of directors (the “Board”) and Chairman of the Board effective June 18, 2025.
Max materiality 0.90 · Median 0.65 · Most common event other_material